Cited by 266Hallucinations in medical conditionsParkinson's Disease Mechanisms and TreatmentsNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Ballanger, Benedicte, Strafella, Antonio P., van Eimeren, Thilo, Zurowski, Mateusz, Rusjan, Pablo M., Houle, Sylvain, Fox, Susan H.·2010·Archives of Neurology

DOI 10.1001/archneurol.2010.35

Open this paper in CoChat — free account

Abstract

BACKGROUND: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. OBJECTIVE: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. DESIGN: Case-control study. SETTING: Academic research. PATIENTS: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. MAIN OUTCOME MEASURES: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. RESULTS: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. CONCLUSIONS: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.

Integrity signals

Registry

Crossref · 10.1001/archneurol.2010.35

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714
A systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Does Fast Dissociation From the Dopamine D 2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model
Gunn, R. N., Lammertsma, A. A., Hume, S. P., & Cunningham, V. J. (1997) · NeuroImage · doi:10.1006/nimg.1997.0303 · Cited by 1,085
The functional organization of human extrastriate cortex: a PET-rCBF study of selective attention to faces and locations
Haxby, J., Horwitz, B., Ungerleider, L. G., Maisog, J. M., Pietrini, P., & Grady, C. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-11-06336.1994 · Cited by 1,065
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035
Depression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A. E., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., STARKSTEIN, S. E., Weintraub, D. A., Poewe, W. H., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 690

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 101–200 of 266

Serotonergic imaging in Parkinson's disease
de Natale, E. R., Wilson, H., & Politis, M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2020.11.001 · Cited by 25
Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias
Creese, B., Ballard, C. G., Aarsland, D., Londos, E., Sharp, S. I., & Jones, E. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.11.001 · Cited by 25
Treating non-motor symptoms of Parkinson’s disease with transplantation of stem cells
Pantcheva, P., Reyes, S., Hoover, J., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1091727 · Cited by 25
Drug treatments for the neuropsychiatric complications of Parkinson’s disease
Connolly, B. S., & Fox, S. H. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.142 · Cited by 24
Self-citation
Imaging behavioural complications of Parkinson’s disease
Valli, M., Mihaescu, A. S., & Strafella, A. P. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9764-1 · Cited by 24
Self-citation
Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease
Kwan, C., Frouni, I., Nuara, S. G., Belliveau, S., Kang, W., Hamadjida, A., Bédard, D., Beaudry, F., Panisset, M., Gourdon, J. C., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108465 · Cited by 22
New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges
Goldman, J. G. (2011) · Parkinson s Disease · doi:10.4061/2011/675630 · Cited by 22
Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine
Dave, S., Weintraub, D., Aarsland, D., & Ffytche, D. H. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12851 · Cited by 21
Shared Genetic Background between Parkinson’s Disease and Schizophrenia: A Two-Sample Mendelian Randomization Study
Kim, K., Kim, S., Myung, W., Shim, I., Lee, H., Kim, B., Cho, S. K., Yoon, J., Kim, D. K., & Won, H. (2021) · Brain Sciences · doi:10.3390/brainsci11081042 · Cited by 21
Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication
Davis, J. M., Zamora, D., Horowitz, M. S., & Leucht, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942455 · Cited by 21
Effect of a hallucinogenic serotonin 5‐HT2A receptor agonist on visually guided, hippocampal‐dependent spatial cognition in C57BL/6J mice
Zhang, G., Cinalli, D. A., & Stackman, R. W. (2017) · Hippocampus · doi:10.1002/hipo.22712 · Cited by 19
Imaging cognitive and behavioral symptoms in Parkinson’s disease
Antonelli, F., Ray, N. J., & Strafella, A. P. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.173 · Cited by 20
Self-citation
Psychiatric Conditions in Parkinson Disease
Buoli, M., Caldiroli, A., & Altamura, A. C. (2015) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988715606233 · Cited by 20
Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Frouni, I., Kwan, C., Nuara, S. G., Belliveau, S., Kang, W., Hamadjida, A., Bédard, D., Gourdon, J. C., & Huot, P. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-020-02287-8 · Cited by 19
Pimavanserin as treatment for Parkinson's disease psychosis
Fox, S. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62157-1 · Cited by 18
Self-citation
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson’s disease and Parkinson’s disease psychosis
Hubbard, D. T., Hacksell, U., & McFarland, K. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283656db6 · Cited by 18
Imaging the Nonmotor Symptoms in Parkinson's Disease
Yousaf, T., Wilson, H., & Politis, M. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.001 · Cited by 18
The Aversion Function of the Limbic Dopaminergic Neurons and Their Roles in Functional Neurological Disorders
He, Z., Jiang, Y., Gu, S., Wu, D., Qin, D., Feng, G., Ma, X., Huang, J. H., & Wang, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.713762 · Cited by 17
In vivo imaging of the integration and function of nigral grafts in clinical trials
Politis, M., & Piccini, P. P. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59575-1.00009-0 · Cited by 17
Parkinson’s Disease Psychosis: Therapy Tips and the Importance of Communication Between Neurologists and Psychiatrists
Martínez-Ramírez, D., Okun, M. S., & Jaffee, M. S. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0009 · Cited by 17
Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed
Citrome, L., Norton, J. C., Chi‐Burris, K., & Demos, G. (2017) · CNS Spectrums · doi:10.1017/s1092852917000736 · Cited by 18
Cognitive and visual processing performance in Parkinson's disease patients with vs without visual hallucinations: A meta-analysis
Montagnese, M., Vignando, M., Ffytche, D. H., & Mehta, M. A. (2021) · Cortex · doi:10.1016/j.cortex.2021.11.001 · Cited by 17
Aberrant resting-state oscillatory brain activity in Parkinson's disease patients with visual hallucinations: An MEG source-space study
Dauwan, M., Hoff, J. I., Vriens, E. M., Hillebrand, A., Stam, C. J., & Sommer, I. E. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101752 · Cited by 19
Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers
Sgambato, V., & Tremblay, L. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1871-7 · Cited by 16
Affective disorders in Parkinsonʼs disease
Aminian, K., & Strafella, A. P. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328363304c · Cited by 16
Self-citation
Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis
Panchal, S. C., & Ondo, W. G. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0869-z · Cited by 17
Grey matter volume loss in Parkinson’s disease psychosis and its relationship with serotonergic gene expression: A meta-analysis
Pisani, S., Gunasekera, B., Lu, Y., Vignando, M., Ffytche, D. H., Aarsland, D., Chaudhuri, К. R., Ballard, C. G., Lee, J., Kim, Y. K., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105081 · Cited by 14
Serotonin in synucleinopathies
Hsam, O., & Kohl, Z. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114367 · Cited by 14
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
Salinsky, L. M., Merritt, C. R., Zamora, J. C., Giacomini, J. L., Anastasio, N. C., & Cunningham, K. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1239159 · Cited by 14
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s Disease: Beyond the Primary Mechanism of Action
Rinaldi, D., Alborghetti, M., Bianchini, E., Sforza, M., Galli, S., & Pontieri, F. E. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220905102144 · Cited by 13
Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson’s Disease
Marino, G., Campanelli, F., Natale, G., Carluccio, M. D., Servillo, F., Ghiglieri, V., & Calabresi, P. (2025) · Current Neuropharmacology · doi:10.2174/011570159x336597241217062042 · Cited by 14
Functional imaging of non-motor signs in Parkinson's disease
Ballanger, B., Poisson, A., Broussolle, E., & Thobois, S. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.11.008 · Cited by 15
Self-citation
Changes in 5-HT 2A Receptor Expression in Untreated, de novo Patients with Parkinson's Disease
Melse, M., Tan, S. K. H., Temel, Y., van Kroonenburgh, M. J. P. G., & Leentjens, A. F. G. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130300 · Cited by 13
New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson’s Disease
Kelberman, M. A., & Vazey, E. M. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0071-0 · Cited by 13
Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics
Butala, A., Shepard, M. D., & Pontone, G. M. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00007-1 · Cited by 13
Pimavanserin for the treatment of Parkinson’s disease psychosis
Chendo, I., & Ferreira, J. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1234609 · Cited by 13
Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges
Brüge, A., Ponimaskin, E. G., & Labus, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100071 · Cited by 13
Radioligand Binding to Brain Dopamine and Serotonin Receptors and Transporters in Parkinson's Disease: Relation to Gene Polymorphisms
Güzey, C., Allard, P. O., Brännström, T., et al. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2011.631716 · Cited by 12
Brain 5-HT2A receptor binding and its neural network related to behavioral inhibition system
Kojima, K., Hirano, S., Kimura, Y., Seki, C., Ikoma, Y., Takahata, K., Ito, T., Yokokawa, K., Hashimoto, H., Kawamura, K., et al. (2022) · Brain Imaging and Behavior · doi:10.1007/s11682-021-00609-2 · Cited by 12
Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms
Zhang, S., & Ma, Y. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i9.1127 · Cited by 12
Modelling perception as a hierarchical competition differentiates imagined, veridical, and hallucinated percepts
Sulfaro, A. A., Robinson, A. K., & Carlson, T. A. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad018 · Cited by 12
Phenotypic Screening of the Prestwick Library for Treatment of Parkinson's Tremor Symptoms using a Humanized Quantitative Systems Pharmacology Platform
Spiros, Ä., Roberts, P., & Geerts, H. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130211 · Cited by 12
Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson’s Disease
Chung, S. J., Lee, S., Yoo, H. S., Lee, Y. H., Lee, H. S., Choi, Y., Lee, P. H., Yun, M., & Sohn, Y. H. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202127 · Cited by 12
Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease
Prange, S., Météreau, É., Klinger, H., Huddlestone, M., Oliveira, M. D., Duperrier, S., Courault, P., Redouté, J., Tremblay, L., Sgambato, V., et al. (2025) · Brain · doi:10.1093/brain/awaf087 · Cited by 13
Advances in the pharmacotherapeutic management of dementia with Lewy bodies
Palermo, G., Ceravolo, R., & Bonuccelli, U. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519548 · Cited by 13
Psychosis in Parkinson's disease: Therapeutic options
Hasnain, M. (2011) · Drugs of today · doi:10.1358/dot.2011.47.5.1584113 · Cited by 11
Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease
Stocchi, F., Fossati, B., & Torti, M. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1804550 · Cited by 10
Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
Touma, K. T. B., & Touma, D. C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.230 · Cited by 10
Nondopaminergic Treatments for Parkinson’s Disease
Huot, P., & Fox, S. H. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.62 · Cited by 10
Self-citation
Face pareidolia is associated with right striatal dysfunction in drug-naïve patients with Parkinson’s disease
Murakami, H., Shiraishi, T., Umehara, T., et al. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05238-7 · Cited by 10
New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease
Taddei, R. N., Spinnato, F., & Jenner, P. G. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.03.004 · Cited by 9
5-HT 2A Receptors and Parkinson’s Disease Psychosis: A Pharmacological Discussion
Huot, P. (2018) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0039 · Cited by 9
Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease
Younes, K., Rojas, J. C., Wolf, A. A., Sheng‐Yang, G. M., Paoletti, M., Toller, G., Caverzasi, E., Mandelli, M. L., Illán‐Gala, I., Kramer, J. H., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51290 · Cited by 9
Progress Regarding Parkinson's Disease Psychosis: It's No Illusion
Weintraub, D. A. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12377 · Cited by 10
Hallucinogenic mechanisms: pathological and pharmacological insights
Lewis, S. J. G., Shine, J. M., Brooks, D., & Halliday, G. M. (2014) · Wiley eBooks · doi:10.1002/9781118892794.ch6 · Cited by 9
Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease
Broadstock, M., Ballard, C. G., & Corbett, A. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.966814 · Cited by 8
Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin
Lyons, K. E., Pahwa, R., Hermanowicz, N. S., Davis, T. L., Pagán, F., & Isaacson, S. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1623669 · Cited by 8
Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments
Rojas, M., Chávez-Castillo, M., Durán, P., Ortega, Á., Bautista-Sandoval, M. J., Salazar, J. J., Riaño-Garzón, M., Chacín, M., Medina, Ó., Palmar, J., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220428102802 · Cited by 11
Visual Hallucinations and Illusions
Liu, G. T., Volpe, N. J., & Galetta, S. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-34044-1.00012-2 · Cited by 8
Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson’s Disease: What Do Clinical and Neuroimaging Studies Tell Us?
Hanganu, A., & Monchi, O. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0907-6 · Cited by 8
Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease
Woo, K. A., Joun, J. H., Yoon, E. J., Lee, C. Y., Jeon, B., Kim, Y. K., & Lee, J. (2023) · Movement Disorders · doi:10.1002/mds.29623 · Cited by 7
Parkinson-Krankheit und Psychosen
Bizzarri, J. V., Giupponi, G., Maniscalco, I., Schroffenegger, P., Conca, A., & Kapfhammer, H. (2015) · Neuropsychiatrie · doi:10.1007/s40211-014-0132-8 · Cited by 7
Serotonin in Parkinson's disease
Kohl, Z., & Winkler, J. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00050-5 · Cited by 7
Lewy Body Degenerations as Neuropsychiatric Disorders
Hinkle, J. T., & Pontone, G. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.003 · Cited by 7
Visual mismatch negativity in Parkinson's psychosis and potential for testing treatment mechanisms
Vignando, M., ffytche, D., Mazibuko, N., Palma, G., Montagnese, M., Dave, S., Nutt, D. J., Gabay, A. S., Tai, Y. F., Batzu, L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae291 · Cited by 6
Neuroimaging and Pathology Biomarkers in Parkinson’s Disease and Parkinsonism
Cilia, R., Arnaldi, D., Ballanger, B., Ceravolo, R., Micco, R. D., Sole, A. D., Eleopra, R., Endo, H., Fasano, A. A., Hoenig, M. C., et al. (2026) · Brain Sciences · doi:10.3390/brainsci16010110 · Cited by 6
Self-citation
Cognitive and Psychiatric Disturbances in Parkinson’s Disease
Aarsland, D., Ehrt, U., & Rektorová, I. (2011) · Aging Health · doi:10.2217/ahe.11.3 · Cited by 6
Management of Parkinson’s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching
Isaacson, S., Nasrallah, H. A., Pahwa, R., Alva, G., Kremens, D. E., & Stahl, S. M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2481205 · Cited by 6
Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson’s Disease
Pachi, I., Papadopoulos, V., Koros, C., Simitsi, A., Bougea, A. M., Bozi, M., Papagiannakis, N., Soldatos, R. F., Kolovou, D., Pantes, G. V., et al. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230056 · Cited by 6
A Novel Synthesis of Pimavanserin: A Selective Serotonin 5-HT2A Receptor Inverse Agonist
Hu, K., Zhang, M., Wu, D., et al. (2020) · Organic Preparations and Procedures International · doi:10.1080/00304948.2019.1697613 · Cited by 6
Connectome-based brain fingerprints predict early cognitive decline in Parkinson’s patients with minor hallucinations
Stampacchia, S., Bernasconi, F., Van De Ville, D., Amico, E., Pagonabarraga, J., Kulisevsky, J., & Blanke, O. (2025) · doi:10.1101/2025.04.17.649310 · Cited by 5
Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats
Vejmola, Č., Šíchová, K., Syrová, K., Janečková, L., Koudelka, V., Tesař, M., Nikolič, M., Viktorinová, M., Tylš, F., Korčák, J., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100524 · Cited by 7
Targeting the Roots of Psychosis: The Role of Aberrant Salience
Marano, G., Lisci, F. M., Sfratta, G., Marzo, E. M., Abate, F., Boggio, G., Traversi, G., Mazza, O., Pola, R., Gaetani, E., et al. (2025) · Pediatric Reports · doi:10.3390/pediatric17030063 · Cited by 8
Differential responses to JNJ‐37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague–Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics
Waal, E. J. D., Desmidt, M., Korte, S., Niehoff, M. O., Chase, K., Arrowsmith, W., & Lampo, A. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2916 · Cited by 5
Fatigue is associated with the onset of hallucinations in patients with Parkinson's disease: A 3-year prospective study
Ikeda, M., Kataoka, H., & Ueno, S. (2016) · eNeurologicalSci · doi:10.1016/j.ensci.2016.04.001 · Cited by 5
Mutual influence of serotonin and dopamine on the functioning of the dorsal striatum and motor activity (hypothetical mechanism)
Silkis, I. G. (2014) · Neurochemical Journal · doi:10.1134/s1819712414030118 · Cited by 4
Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Nuara, S. G., Gourdon, J. C., Maddaford, S. P., & Huot, P. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02162-7 · Cited by 4
Psychosis in Parkinson’s Disease and Current Management Trends- an Updated Review of Literature
Dutta, R. (2023) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001078 · Cited by 4
Neuroimaging Findings in Patients with Hallucinations: Evidence from Neurodegenerative and Psychiatric Conditions
Pezzoli, S., & Venneri, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_17 · Cited by 4
Ursachen visueller Halluzinationen bei der Parkinson-Krankheit
Diederich, N. J. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01165-2 · Cited by 4
Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine
Sgambato, V. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.07.015 · Cited by 4
Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group
Namasivayam, A. A., Fischer, C. E., Abler, V., Creese, B., Gastiazoro, M. P., Hermida, A. P., Ikeda, M., Ismail, Z., Jeste, D. V., McDermid, J., et al. (2025) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100133 · Cited by 3
Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases
Heller, N. H., Barrett, F. S., Buchborn, T., Collerton, D., Dupuis, D., Halberstadt, A. L., Jardri, R., Noorani, T. N., Preller, K. H., Taylor, J., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf068 · Cited by 3
Cognitive effects of quetiapine in a patient with dementia with Lewy bodies
Rice, T., Dobry, Y., Eugene, W. A. N. G., et al. (2013) · Psychogeriatrics · doi:10.1111/j.1479-8301.2012.00414.x · Cited by 3
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
Majláth, Z., Obál, I., & Vécsei, L. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161006104347 · Cited by 3
Global research trends and hotspots in Parkinson’s disease psychosis: a 25-year bibliometric and visual analysis
Wu, J., Jin, X., Xie, W., Liu, L., Wang, F., Zhu, L., Shen, Y., & Qiu, L. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1480234 · Cited by 2
A high-performance genetically encoded sensor for cellular imaging of PKC activity in vivo
Yahiro, T., Bayless-Edwards, L., Jones, J. A., Zhuo, Y., Ma, L., Qin, M., Mao, T., & Zhong, H. (2025) · Nature Communications · doi:10.1038/s41467-025-61729-7 · Cited by 2
How Layer-Specific fMRI Can Contribute to Understanding Perceptual Disturbances Across Psychiatric Disorders
Haarsma, J., & Kok, P. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_595 · Cited by 2
Paediatric migraine with visual hallucination auras appearing in the form of a human body
Akiyama, O., Kondo, A., & Akiyama, I. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-232358 · Cited by 2
PET and SPECT Findings in Patients with Hallucinations
Bossong, M. G., & Allen, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_20 · Cited by 2
A Probable Case of Peduncular Hallucinosis Status Postthalamic and Cerebral Peduncle Cerebrovascular Accident Treated Successfully With Risperidone
Spiegel, D. R., Rivers, J. W., & Peglow, S. L. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13080179 · Cited by 2
Management of Nonmotor Symptoms of Parkinson's Disease
Gálvez-Jiménez, N., Fernandez, H. H., Espay, A. J., & Fox, S. H. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107284210.010 · Cited by 2
Self-citation
A New Perspective in the Treatment of Parkinson’s Disease Psychosis
Pahwa, R., & Lyons, K. E. (2016) · touchREVIEWS in Neurology · doi:10.17925/usn.2016.12.02.93 · Cited by 2
Charles Bonnet Syndrome Treated With Pimavanserin
Boren, R. A., & Boren, C. B. (2019) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000800 · Cited by 2
The Possible Mechanism of the Appearance of Nightmares in Post-Traumatic Stress Disorder and Approaches to Their Prevention
Silkis, I. G. (2019) · Neurochemical Journal · doi:10.1134/s1819712419030127 · Cited by 2
Therapies under investigation for treating Parkinson's disease psychosis
Huynh, N. T., & Huot, P. (2014) · Clinical Investigation · doi:10.4155/cli.14.84 · Cited by 2
Beyond Dopamine
Velakoulis, D., Mocellin, R., Evans, A. H., & Walterfang, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00024-x · Cited by 1
Exploring Psilocybin as a Tool for Studying Parkinsonism-Related Psychosis: A Narrative Review Supplemented with a Computational Approach
Čampara, A., & Kovačić, D. (2024) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-031-49068-2_54 · Cited by 1
Roles of molecular neuroimaging techniques in Parkinsonism
Singer, E. D., Bhatt, K. P., Anthony, A. T., Dabjan, M. B., Muhammad, S., Tsai, J., & Michel, G. (2023) · Discoveries · doi:10.15190/d.2023.16 · Cited by 1
Effect of the mGlu2 receptor positive allosteric modulator AZD8529 on L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Shaqfah, J., Bédard, D., Nuara, S. G., Gourdon, J. C., Hamadjida, A., Gaudette, F., Beaudry, F., & Huot, P. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178031 · Cited by 1

Authors: Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H.
Affiliations: Montreal Neurological Institute and Hospital (CA)
ORCID: Strafella, Antonio P.
Zurowski, Mateusz
Rusjan, Pablo M.
Houle, Sylvain
Fox, Susan H.
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2010-04-01
Volume: 67
Issue: 4
Pages: 416-21
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneurol.2010.35
OpenAlex: W2026136738
Cited by: 266
References: 29
Citations by year: 2026: 12 · 2025: 17 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 17 · 2020: 21 · 2019: 18 · 2018: 19 · 2017: 24 · 2016: 26 · 2015: 8 · 2014: 19 · 2013: 25 · 2012: 7
FWCI: 9.86
Type: journal article
Language: en
Open access: closed
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: 5-HT2A receptor, complex visual hallucinations, Parkinson's disease, ventral stream, serotonergic neurotransmission, dopamine, receptor binding imaging, prefrontal cortex, fusiform gyrus, inferotemporal cortex
MeSH terms: Aged, Brain, Brain Mapping, Female, Hallucinations, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Pyrimidinones, Serotonin, Serotonin Antagonists, Temporal Lobe, Visual Cortex, Visual Pathways, Case-Control Studies, Receptor, Serotonin, 5-HT2A, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks